MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition |
Cao, Lanqin
(Department of Obstetrics, Xiangya Hospital, Central South University)
Wan, Qian (Department of Obstetrics, Xiangya Hospital, Central South University) Li, Fengjie (Department of Obstetrics, Xiangya Hospital, Central South University) Tang, Can-e (The Institute of Medical Science Research, Xiangya Hospital, Central South University) |
1 | Chen Y, Lu X, Wu B, Su Y, Li J and Wang H (2015) MicroRNA 363 mediated positive regulation of c-myc translation affect prostate cancer development and progress. Neoplasma 62, 191-198 DOI |
2 | Conti A, Romeo SG, Cama A et al (2016) MiRNA expression profiling in human gliomas: upregulated miR-363 increases cell survival and proliferation. Tumour Biol 37, 14035-14048 DOI |
3 | Lin Y, Xu T, Zhou S and Cui M (2017) MicroRNA-363 inhibits ovarian cancer progression by inhibiting NOB1. Oncotarget 8, 101649-101658 |
4 | Huang H, Chen J, Ding CM, Jin X, Jia ZM and Peng J (2018) LncRNA NR2F1-AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR-363. J Cell Mol Med 22, 3238-3245 DOI |
5 | Zhang P, Zhang P, Shi B et al (2014) Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer. Cell Death Dis 5, e991 DOI |
6 | Boyerinas B, Park SM, Murmann AE et al (2012) Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int J Cancer 130, 1787-1797 DOI |
7 | Chin LJ, Ratner E, Leng S et al (2008) A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res 68, 8535-8540 DOI |
8 | Liu C, Kelnar K, Vlassov AV, Brown D, Wang J and Tang DG (2012) Distinct microRNA expression profiles in prostate cancer stem/progenitor cells and tumor-suppressive functions of let-7. Cancer Res 72, 3393-3404 DOI |
9 | Cai J, Yang C, Yang Q et al (2013) Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to cisplatin. Oncogenesis 2, e75 DOI |
10 | Yu F, Yao H, Zhu P et al (2007) let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131, 1109-1123 DOI |
11 | Hsu DS, Lan HY, Huang CH et al (2010) Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer. Clin Cancer Res 16, 4561-4571 DOI |
12 | Kaufhold S and Bonavida B (2014) Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention. J Exp Clin Cancer Res 33, 62 DOI |
13 | Haslehurst AM, Koti M, Dharsee M et al (2012) EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer 12, 91 DOI |
14 | Zamble DB and Lippard SJ (1995) Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 20, 435-439 DOI |
15 | Zhuo W, Wang Y, Zhuo X, Zhang Y, Ao X and Chen Z (2008) Knockdown of Snail, a novel zinc finger transcription factor, via RNA interference increases A549 cell sensitivity to cisplatin via JNK/mitochondrial pathway. Lung Cancer 62, 8-14 DOI |
16 | Chiu WT, Huang YF, Tsai HY et al (2015) FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells. Oncotarget 6, 2349-2365 |
17 | Kuchenbaecker KB, Ramus SJ, Tyrer J et al (2015) Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet 47, 164-171 DOI |
18 | Raghavan R, Hyter S, Pathak HB et al (2016) Drug discovery using clinical outcome-based Connectivity Mapping: application to ovarian cancer. BMC Genomics 17, 811 DOI |
19 | Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265-7279 DOI |
20 | Siegel R, Naishadham D and Jemal A (2012) Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin 62, 283-298 DOI |
21 | Polyak K and Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9, 265-273 DOI |
22 | Johnson CD, Esquela-Kerscher A, Stefani G et al (2007) The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 67, 7713-7722 DOI |
23 | Marchini S, Fruscio R, Clivio L et al (2013) Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur J Cancer 49, 520-530 DOI |
24 | Calin GA and Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6, 857-866 DOI |
25 | Chang TC, Yu D, Lee YS et al (2008) Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 40, 43-50 DOI |
26 | Hu F, Min J, Cao X et al (2016) MiR-363-3p inhibits the epithelial-to-mesenchymal transition and suppresses metastasis in colorectal cancer by targeting Sox4. Biochem Biophys Res Commun 474, 35-42 DOI |
27 | Tsai WC, Hsu SD, Hsu CS et al (2012) MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 122, 2884-2897 DOI |
28 | Liu J, Li Q, Li R, Ren P and Dong S (2017) MicroRNA-363-3p inhibits papillary thyroid carcinoma progression by targeting PIK3CA. Am J Cancer Res 7, 148-158 |
29 | Zhang PF, Sheng LL, Wang G et al (2016) miR-363 promotes proliferation and chemo-resistance of human gastric cancer via targeting of FBW7 ubiquitin ligase expression. Oncotarget 7, 35284-35292 DOI |
30 | Zhang R, Li Y, Dong X, Peng L and Nie X (2014) MiR-363 sensitizes cisplatin-induced apoptosis targeting in Mcl-1 in breast cancer. Med Oncol 31, 347 DOI |
31 | Li Y, Chen D, Li Y et al (2016) Oncogenic cAMP responsive element binding protein 1 is overexpressed upon loss of tumor suppressive miR-10b-5p and miR-363-3p in renal cancer. Oncol Rep 35, 1967-1978 DOI |